Hemophilia is an inherited bleeding disorder caused by deficiencies in clotting factor VIII, in the case of hemophilia A, or factor IX, in the case of hemophilia B. Because these proteins are essential for forming stable blood clots, affected individuals bleed for longer than normal after injury and can bleed spontaneously into joints, muscles, and, most dangerously, the brain. The disorder is passed on through the X chromosome, so it overwhelmingly affects boys, while girls are typically carriers. What makes the neonatal period so treacherous is the combination of an immature coagulation system, the mechanical stresses of labor and delivery, and the fact that many affected infants are born into families with no known history of the disease. In roughly a third of cases, hemophilia appears in a child with no prior family history, arising from a new genetic mutation, which means neither obstetricians nor parents may anticipate the bleeding risk before delivery.

Intracranial hemorrhage in a newborn is a medical emergency of the highest order. Bleeding can occur in several compartments of the skull: inside the brain tissue itself, in the subdural space beneath the dura mater, in the subarachnoid space surrounding the brain, or within the ventricles, the fluid-filled cavities deep in the brain. In a baby with hemophilia, even a minor trauma during delivery, such as the pressure of forceps, a vacuum extraction, or a prolonged second stage of labor, can trigger bleeding that a healthy infant’s clotting system would quickly contain. Symptoms may include seizures, lethargy, vomiting, a bulging fontanelle, pallor, or simply poor feeding and irritability, and because these signs overlap with many other neonatal conditions, diagnosis is often delayed. Untreated, the bleed can expand, compressing brain tissue and causing permanent damage or death.

The true scale of the problem has long been difficult to pin down. Previous estimates of neonatal ICH risk in hemophilia have ranged widely across the literature, from figures below one percent to reports suggesting rates several times higher. The authors of the new analysis attribute this fragmentation to heterogeneous study designs, small single-center cohorts, differing diagnostic criteria, and inconsistent surveillance practices. Some studies relied on clinical symptoms alone, others on routine cranial imaging, and the era in which each study was conducted matters as well, since the availability of neonatal ultrasound, computed tomography, and magnetic resonance imaging has changed dramatically over recent decades. By systematically searching PubMed, Embase, and Scopus from their inception through November 2025 and applying consistent eligibility criteria, requiring reported ICH within the first twenty-eight days of life among live-born neonates with hemophilia, the team sought to produce the most reliable estimate to date.

The statistical machinery behind the study is standard for modern evidence synthesis but worth unpacking. Rather than simply averaging the results of the thirteen included studies, the researchers used a random-effects meta-analysis, a model that assumes each study estimates its own true incidence and that these true values are distributed around a common mean. This approach is appropriate when between-study heterogeneity is high, which the authors confirmed it was. Heterogeneity in this context means the studies differed substantially in their reported rates, likely reflecting differences in geography, era, severity of hemophilia represented, mode of delivery, and intensity of diagnostic workup. The random-effects model widens the confidence interval to account for this variability, which is why the pooled estimate of 2.10 percent carries an interval stretching from 1.40 to 2.79 percent rather than a razor-thin range.

One of the more sobering findings concerns mortality. The pooled estimate for fatal neonatal ICH was approximately 0.2 percent, with a 95 percent confidence interval of 0.0 to 1.2 percent. In other words, among every thousand live-born neonates with hemophilia, roughly two may die from a brain bleed in the first month of life, though the wide interval reflects the rarity of the event and the limits of the available data. Fatal bleeds were rare in absolute terms, but the analysis underscores that when ICH does occur, it carries the potential for catastrophic outcomes. Survivors of neonatal ICH can face cerebral palsy, epilepsy, developmental delay, and cognitive impairment, making prevention far more valuable than even the best acute treatment.

Prevention, the authors argue, hinges on three pillars: early diagnosis, careful perinatal management, and avoidance of traumatic delivery techniques. Early diagnosis means identifying at-risk infants before or immediately after birth, ideally through known family history, carrier testing, or, in some health systems, targeted newborn screening of male infants born to carrier mothers. Careful perinatal management involves coordinating obstetric and hematology teams well before delivery, planning the mode of birth to minimize trauma, and avoiding invasive monitoring such as fetal scalp electrodes or vacuum and rotational forceps deliveries when a baby is known or suspected to have hemophilia. For infants diagnosed after birth, prompt replacement of the missing clotting factor can halt bleeding before it spreads, and some guidelines recommend prophylactic factor replacement for high-risk neonates during the vulnerable first days of life.

The study’s findings arrive amid a broader shift in hemophilia care. Prophylactic clotting factor infusions, once reserved for older children with severe disease, are increasingly considered earlier, and newer agents, including extended half-life factor products and bispecific antibodies that mimic factor VIII activity, have transformed long-term management. Yet the neonatal window remains a blind spot in many treatment pathways, because diagnosis itself may lag behind the highest-risk period. The authors call for dedicated neonatal-focused registries and prospective studies to refine risk stratification, arguing that only systematically collected, individual-level data can identify which babies are most likely to bleed and which preventive strategies work best. Such registries could track delivery mode, factor levels at birth, family history, imaging findings, and outcomes in a standardized way across centers and countries.

The meta-analysis also highlights persistent gaps in the evidence base. The thirteen included studies spanned different decades, healthcare settings, and diagnostic standards, and the authors note that the substantial heterogeneity between them limits the precision of any single pooled estimate. Retrospective designs dominated, and few studies distinguished between severity categories of hemophilia, modes of delivery, or the timing and type of diagnostic imaging. Without prospective, standardized surveillance, some bleeds may go undetected, particularly small hemorrhages that produce subtle or absent symptoms in the first days of life. This means the true incidence could, in principle, be higher than the pooled estimate suggests, a possibility the authors acknowledge indirectly through their call for better data.

For clinicians and families, the practical message is clear. A 2.10 percent risk is low enough that most newborns with hemophilia will never experience a brain bleed, but high enough that every birth should be treated as an opportunity for prevention. When hemophilia is known or suspected before delivery, obstetric teams can choose the least traumatic route of birth, neonatologists can maintain a low threshold for cranial imaging, and hematologists can have replacement factor ready at the bedside. When there is no family history, the challenge is harder, but the growing availability of genetic carrier screening and heightened awareness among providers can shorten the path from first symptom to diagnosis and treatment. The study, published open access on October 6, 2026, and citable under DOI 10.1186/s12887-026-07750-1, adds a carefully quantified data point to a field that has long operated on fragmented numbers, and it makes a compelling case that the first twenty-eight days of life deserve far more systematic attention in the care of children with hemophilia.

Subject of Research: Neonatal intracranial hemorrhage risk in infants with hemophilia

Article Title: Risk of intracranial hemorrhage in neonates with hemophilia: a systematic review and meta-analysis

Article References: Zheng, M., Zheng, H., Li, Y., & Tu, J. (2026). Risk of intracranial hemorrhage in neonates with hemophilia: a systematic review and meta-analysis. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07750-1

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07750-1

Keywords: hemophilia, intracranial hemorrhage, neonatology, meta-analysis, systematic review, clotting factors, bleeding disorders, perinatal care, newborn screening, prophylaxis, BMC Pediatrics, birth trauma

The survey gathered 1,167 completed interviews online via SurveyMonkey, with data provided to SSRS for formal analysis in August 2026. Respondents included patients, caregivers, healthcare providers, and patient advocates from around the world, giving the results a breadth that few single-condition studies can match. What emerges is a picture of medical dependence that is both chronic and intimate: roughly two in three respondents reported that they, or someone they care for, receive plasma-derived medicines at least once a month, and 41 percent said treatment occurs weekly. For these families, plasma therapy is not an occasional intervention but a recurring rhythm of life, scheduled around infusions, clinic visits, and the constant logistics of maintaining a supply of medicine that exists only because someone else volunteered to donate.

The conditions that drive this dependence are diverse, but they share a common thread: the body’s own biochemistry has failed in a way that only donated human plasma can reliably correct. Nearly half of respondents said they or someone they care for receive plasma-derived medicines for an immunodeficiency, 18 percent for a bleeding or blood disorder, 16 percent for a neurological condition, and 15 percent for a lung-related illness. Primary immunodeficiencies, a group of more than 400 inherited disorders in which part of the immune system is missing or malfunctioning, are among the most prominent indications. Patients with these conditions lack adequate antibodies of their own, and the immunoglobulin therapies derived from pooled donor plasma effectively replace that missing molecular armor, shielding them from infections that most people shrug off without noticing.

The technical journey from a donor’s arm to a patient’s infusion bag is one of the more remarkable processes in modern biomedicine. Once collected, plasma from thousands of individual donations is pooled and subjected to fractionation, a carefully sequenced separation process that exploits differences in protein solubility and behavior to isolate specific therapeutic components. Immunoglobulins, clotting factors such as Factor VIII for hemophilia, albumin for treating shock and burns, and other proteins are each extracted, purified, and subjected to multiple viral inactivation and removal steps. Because many of these proteins cannot yet be produced synthetically at scale, donated human plasma remains the only practical source. That biological reality is what binds a donor in Addison, Illinois, to a patient on another continent, and it is why the industry built around fractionation is often described as a unique sector of the biologics and biotechnology landscape.

The survey’s most striking finding concerns speed of effect. More than two-thirds of respondents, 69 percent, noticed a change in their health, or in the health of someone they care for, within a few months of beginning a plasma-derived medicine, and 26 percent noticed a change within just a few days. For clinicians who treat immunodeficiency or bleeding disorders, this rapid response is familiar territory: a child with hemophilia who receives a clotting factor concentrate can stop a spontaneous joint bleed within hours, and an immunodeficient patient beginning immunoglobulin replacement often reports a dramatic reduction in the frequency and severity of infections within the first months of therapy. The survey data translate that clinical observation into a population-level statistic, quantifying how quickly these biologics alter the daily experience of illness.

Confidence in the medicines themselves is correspondingly high. Fully 87 percent of patients expressed confidence in the safety and efficacy of plasma-derived therapies, a figure that reflects decades of incremental improvement in donor screening, pathogen detection, and manufacturing controls. Modern plasma products undergo nucleic acid testing for blood-borne viruses, hold periods that allow emerging infections to be detected before pools are released, and redundant viral clearance steps during fractionation. That layered safety architecture, developed and refined since the challenges of the 1980s, underpins the trust that patients report in the survey and allows these therapies to be delivered into veins on a weekly basis with a risk profile that patients and their physicians consider acceptable for lifelong use.

Gratitude emerges as the emotional throughline of the findings. More than three-quarters of respondents, 77 percent, described themselves as grateful to plasma donors, an expression that the survey’s sponsors hope will translate into more people rolling up their sleeves. Behind the statistic are individual stories that illustrate what the numbers mean in practice. Christy Savino, a plasma recipient diagnosed with a primary immunodeficiency, described the impact in personal terms: the therapy allows her family to make memories together, a gift of life she described as present in every moment of every day and traveling with the family wherever they go. Her husband, Antonio Savino, donates plasma regularly at a BioLife Plasma Services donation center in Addison, Illinois, in her honor, a concrete example of the donor-to-patient loop that the awareness week is designed to celebrate.

Patient advocacy organizations see the survey as an opportunity to widen the circle of people who understand where these medicines come from. Jorey Berry, President and CEO of the Immune Deficiency Foundation, noted that this year’s International Plasma Awareness Week campaign shines a light on people and families living with immunodeficiencies and other rare diseases, and emphasized that for many patients these medicines are not merely treatments but what makes everyday life possible. His message to potential donors is direct: every plasma donation matters deeply, and donating offers healthy people a tangible way to give patients the chance to live healthier, fuller lives. The campaign’s framing, that plasma powers possibility, is an attempt to convert abstract appreciation into the specific act of booking a donation appointment.

The scale of the enterprise behind these therapies is easy to underestimate. The Plasma Protein Therapeutics Association, which represents the manufacturers and collectors of plasma protein therapies, counts more than 1,000 plasma collection centers across North America and Europe among its members. Those members produce approximately 80 percent of the plasma protein therapies used in the United States and approximately 60 percent of those used in Europe. Meeting global demand requires millions of donations each year, because a single patient’s annual immunoglobulin supply can require donations from hundreds or even thousands of individual donors over the course of a year of fractionated production. The arithmetic of that supply chain explains why donor recruitment is a permanent, global public health effort rather than a one-time campaign.

For the patients and caregivers who answered the survey, the message that emerges is one of quiet, ongoing dependence paired with remarkable resilience. The age at which treatment began varied widely among respondents, though the largest share, 49 percent, said they or someone they care for first received a plasma-derived medicine between the ages of 36 and 64, indicating that these therapies enter lives at every stage, not only in childhood. What unites them is the experience of a medicine that works quickly, is trusted deeply, and exists only through the generosity of strangers. International Plasma Awareness Week, which runs through the week beginning October 5, asks the public to see that connection clearly: behind every vial of immunoglobulin or clotting factor is a person who took an hour to donate, and behind every donor is a patient whose ordinary day, and ordinary family memories, depend on it. Information about donation and patient stories is available at plasmaweek.org and through the association’s donation center locator.

Subject of Research: Global patient survey on the use, impact, and perceived safety of plasma-derived medicines and the role of plasma donors

Article Title: New global survey shines a light on the patients who rely on plasma-derived medicines—and the donors who make them possible

Article References: New global survey shines a light on the patients who rely on plasma-derived medicines—and the donors who make them possible. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: plasma donation, plasma-derived medicines, plasma protein therapeutics, primary immunodeficiency, immunoglobulin therapy, bleeding disorders, International Plasma Awareness Week, patient survey, SSRS, PPTA, fractionation, rare diseases